Shots:

• Moderna reported the publication of the second interim analysis of the open-label P-I study of mRNA-1273 in the NEJM. The study evaluated a 2dose vaccination schedule of mRNA-1273 given 28 days apart in 40 adults across two dose levels (25/100µg) in two age cohorts (56-70/ 71+) and reports results @Day 57 (1mos. following the second dose)
• mRNA-1273 induced consistently high levels of pseudovirus neutralization Ab titers in all participants- elicited Th1-biased CD4 T cell responses across all age group- neutralizing Ab titers and T cell responses is consistent with reported in younger adults- both the doses were well tolerated
• Results were consistent using 3 live virus assays. Additionally- the US government has agreed to purchase 100M doses of mRNA-1273- with an option to purchase an additional 400M dose

­ Ref: Moderna | Image: Moderna